Reports indicate that SGLT-2 inhibitors notably boost autophagy in liver macrophages through the AMPK/mTOR signaling axis, alleviating liver damage in T2DM mice with NAFLD [39]. Here, SLC5A2 is linked to type 2 diabetes mellitus.